Table of Content


Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst’s Credentials

Chapter 2 Summary and Highlights
Highlights of the Market for Epigenetic Therapeutics
Chapter 3 Market Overview and Definitions
Overview
Epigenetics
Chapter 4 Market Trends
Market Drivers
Aging Population
Risk of Cancer in Major Countries
Penetration of Targeted Medicine in Emerging Markets
Market Opportunity
Market Restraints
Chapter 5 Market Breakdown by Product Type
Introduction
PRAP Inhibitors
Kinase Inhibitors
IDH Inhibitors
HDAC Inhibitors
DNMT Inhibitors
KMT Inhibitors
Chapter 6 Impact of COVID-19
Introduction
Impact of COVID-19 on the Medical Devices and Pharmaceutical Industries
Decline/Delay in Elective Procedures
Impact of COVID-19 on Medical Device and Pharmaceutical Product Segments
Impact of COVID-19 on Epigenetic Therapeutics Markets
Chapter 7 Market Breakdown by Region
Market Overview and Discussion
North America
Latin America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Emerging/Upcoming Technologies
CRISPR
Antibody Drug Conjugates
Multitargeting Agents
Chapter 9 Competitive Landscape
Industry Scenario
Company Shares
Chapter 10 Patent Analysis
Patent Analysis, by Manufacturer
Chapter 11 Pipeline Analysis
Clinical Trials Scenario
Chapter 12 Company Profiles
ASTRAZENECA
BRISTOL-MYERS SQUIBB
CLOVIS ONCOLOGY
GSK PLC
INCYTE
IPSEN
SEAGEN
SERVIER LABORATORIES, LTD.
Chapter 13 Appendix: Acronyms



List of Figures

List of Figures
Summary Figure A : Global Epigenetic Therapeutics Market, by Product Type, 2019-2028
Summary Figure B : Global Epigenetic Therapeutics Market Share, by Product Type, 2022
Figure 1 : Global Epigenetic Therapeutics Market, by Product, 2020-2028
Figure 2 : Global Epigenetic Therapeutics Market Share, by Product, 2022
Figure 3 : Global PRAP Inhibitors Market, by Region, 2020-2028
Figure 4 : Global PRAP Inhibitors Market Share, by Region, 2022
Figure 5 : Global Kinase Inhibitors Market, by Region, 2020-2028
Figure 6 : Global Kinase Inhibitors Market Share, by Region, 2022
Figure 7 : Global IDH Inhibitors Market, by Region, 2020-2028
Figure 8 : Global IDH Inhibitors Market Share, by Region, 2022
Figure 9 : Global HDAC Inhibitors Market, by Region, 2020-2028
Figure 10 : Global HDAC Inhibitors Market Share, by Region, 2022
Figure 11 : Global DNMT Inhibitors Market, by Region, 2020-2028
Figure 12 : Global DNMT Inhibitors Market Share, by Region, 2022
Figure 13 : Global KMT Inhibitors Market, by Region, 2020-2028
Figure 14 : Global KMT Inhibitors Market Share, by Region, 2022
Figure 15 : Global Epigenetic Therapeutics Market Share, by Region, 2022
Figure 16 : North American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 17 : Latin American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 18 : European Epigenetic Therapeutics Market Share, by Country, 2022
Figure 19 : Asia-Pacific Epigenetic Therapeutics Market Share, by Country, 2022
Figure 20 : Global Epigenetic Therapeutics Market Share, by Company, 2022
Figure 21 : Global PRAP Inhibitors Market Share, by Company, 2022
Figure 22 : Global Kinase Inhibitors Market Share, by Company, 2022
Figure 23 : Global IDH Inhibitors Market Share, by Company, 2022
Figure 24 : Global HDAC Inhibitors Market Share, by Company, 2022
Figure 25 : Global DNMT Inhibitors Market Share, by Company, 2022
Figure 26 : Global KMT Inhibitors Market Share, by Company, 2022
Figure 27 : AstraZeneca: Sales Share, by Product, 2022
Figure 28 : AstraZeneca: Sales Share, by Region, 2022
Figure 29 : Bristol-Myers Squibb: Sales Share, by Region, 2022
Figure 30 : GSK: Revenue Share, by Product, 2022
Figure 31 : GSK: Sales Share, by Region, 2022
Figure 32 : Ipsen: Sales Revenue Share, by Segment, 2022
Figure 33 : Ipsen: Sales Revenue Share, by Region 2022

List of Tables

List of Tables
Summary Table : Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 1 : Global Population, Age 60 and Older, 2010-2050
Table 2 : Incidence of Pancreas Cancer, 2020-2040
Table 3 : Incidence of Trachea, Bronchus and Lung Cancer, 2020-2040
Table 4 : Incidence of Melanoma Cancer, 2020-2040
Table 5 : Incidence of Prostate Cancer, 2020-2040
Table 6 : Incidence of Breast Cancer, 2020-2040
Table 7 : Incidence of Kidney and Renal Pelvis Cancers, 2020-2040
Table 8 : Incidence of Hodgkin Lymphoma Cancer, 2020-2040
Table 9 : Incidence of Non-Hodgkin Lymphoma Cancer, 2020-2040
Table 10 : Incidence of Multiple Myeloma and Immunoproliferative Diseases, 2020-2040
Table 11 : Incidence of Leukemia Cancer, 2020-2040
Table 12 : Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 13 : Global PRAP Inhibitors Market, by Region, Through 2028
Table 14 : Global Kinase Inhibitors Market, by Region, Through 2028
Table 15 : Global IDH Inhibitors Market, by Region, Through 2028
Table 16 : Global HDAC Inhibitors Market, by Region, Through 2028
Table 17 : Global DNMT Inhibitors Market, by Region, Through 2028
Table 18 : Global KMT Inhibitors Market, by Region, Through 2028
Table 19 : Global Epigenetic Therapeutics Market, by Region, Through 2028
Table 20 : North American Epigenetic Therapeutics Market, by Country, Through 2028
Table 21 : Latin American Epigenetic Therapeutics Market, by Country, Through 2028
Table 22 : European Epigenetic Therapeutics Market, by Country, Through 2028
Table 23 : Asia-Pacific Epigenetic Therapeutics Market, by Country, Through 2028
Table 24 : RoW Epigenetic Therapeutics Market, Through 2028
Table 25 : Patents on Epigenetic Drugs, 2015-April 2023
Table 26 : Selected Manufacturer Patents on Epigenetic Drugs, 2015-April 2023
Table 27 : Patents on HDAC Inhibitors, 2015-April 2023
Table 28 : Selected Manufacturer Patents on HDAC inhibitors, 2015-April 2023
Table 29 : Patents on Kinase inhibitors, 2015-April 2023
Table 30 : Patents on Verinostat Drug, 2015-April 2023
Table 31 : Selected Manufacturer Patents on Verinostat Drug, 2015-April 2023
Table 32 : Patents on Romidepsin Drug, 2015-April 2023
Table 33 : Selected Manufacturer Patents on Romidepsin Drug, 2015-April 2023
Table 34 : Patents on Panobinostat Drug, 2015-April 2023
Table 35 : Selected Manufacturer Patents on Panobinostat Drug, 2015-April 2023
Table 36 : Patents on Belinostat, 2015-April 2023
Table 37 : Selected Manufacturer Patents on Belinostat, 2015-April 2023
Table 38 : Patents on Tucidinostat Drug, 2015-April 2023
Table 39 : Selected Manufacturer Patents on Tucidinostat Drug, 2015-April 2023
Table 40 : Patents on 5-Azacytidine Drug, 2015-April 2023
Table 41 : Selected Manufacturer Patents on 5-Azacytidine Drug, 2015-April 2023
Table 42 : Patents on 5-Aza-2’-Deoxycytidine Drug, 2015-April 2023
Table 43 : Selected Manufacturer Patents on 5-Aza-2’-Deoxycytidine Drug, 2015-April 2023
Table 44 : Patents on Pinometostat Drug, 2015-April 2023
Table 45 : Selected Manufacturer Patents on Pinometostat Drug, 2015-April 2023
Table 46 : Patents on Ruxolitinib Drug, 2015-April 2023
Table 47 : Selected Manufacturer Patents on Ruxolitinib Drug, 2015-April 2023
Table 48 : Patents on AZD1152 Drug, 2015-April 2023
Table 49 : Selected Manufacturer Patents on AZD1152 Drug, 2015-April 2023
Table 50 : Patents on Olaparib Drug, 2015-April 2023
Table 51 : Selected Manufacturer Patents on Olaparib Drug, 2015-April 2023
Table 52 : Patents on Veliparib Drug, 2015-April 2023
Table 53 : Selected Manufacturer Patents on Veliparib Drug, 2015-April 2023
Table 54 : Patents on Niraparib Drug, 2015-April 2023
Table 55 : Selected Manufacturer Patents on Niraparib Drug, 2015-April 2023
Table 56 : Patents on Rucaparib Drug, 2015-April 2023
Table 57 : Selected Manufacturer Patents on Rucaparib Drug, 2015-April 2023
Table 58 : Patents on Talazoparib Drug, 2015-April 2023
Table 59 : Selected Manufacturer Patents on Talazoparib Drug, 2015-April 2023
Table 60 : Selected Kinase Inhibitors in Clinical Trials, as of 2023
Table 61 : Selected Olaparib Inhibitors in Clinical Trials, as of 2023
Table 62 : Selected Romidepsin Inhibitors in Clinical Trials, as of 2023
Table 63 : Selected Ruxolitinib Inhibitors in Clinical Trials, as of 2023
Table 64 : AstraZeneca: Company Annual Revenue, 2019-2022
Table 65 : AstraZeneca: Annual Revenue, by Product, 2022
Table 66 : Bristol-Myers Squibb: Company Annual Revenue, 2019-2022
Table 67 : Clovis Oncology: Revenue, 2019-2021
Table 68 : GSK: Company Annual Revenue, 2019-2022
Table 69 : GSK: Annual Revenue, by Product, 2022
Table 70 : Incyte: Company Annual Revenue, 2019-2021
Table 71 : Incyte: Product Revenue, 2019-2021
Table 72 : Ipsen: Sales Revenue, 2021 and 2022
Table 73 : Ipsen: Sales Revenue, by Segment, 2021 and 2022
Table 74 : Ipsen: Sales Revenue, by Region, 2021 and 2022
Table 75 : Seagen: Company Annual Revenue, 2019-2021
Table 76 : Acronyms Used in this Report